• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

You thought VRX buying you was the worst thing, now look....

Quote

Anonymous

Guest
"Still, many of Allergan’s scientists will be hoping that the “anyone but Valeant” strategy has not ended up with (Activas) the company selling itself to a milder version of the same thing."
 








Anonymous said:
It is less bad. Actavis plans only $450M in R&D cuts vs the $900M that Valeant was talking.
Click to expand...

But just as many total people will lose their jobs. Valeant claimed 2.7B in "synergies" Actavis is claiming 1.8B.

the difference between the two company's tax rates - Irish versus effective Canadian applied to Allergan's Revenues is ~850MM

The "human capital" being cut in both scenarios is almost identical. Plan on about 30% of all Allergan employees being let go. That's on top of the 13% earlier this year (though some of that 13% was pencil pushing open position cuts) about 8% of real employees were cut.

So, when it's all said and done 35-40% of our colleagues and ourselves will be out of a job.
 








Anonymous said:
But just as many total people will lose their jobs. Valeant claimed 2.7B in "synergies" Actavis is claiming 1.8B.

the difference between the two company's tax rates - Irish versus effective Canadian applied to Allergan's Revenues is ~850MM

The "human capital" being cut in both scenarios is almost identical. Plan on about 30% of all Allergan employees being let go. That's on top of the 13% earlier this year (though some of that 13% was pencil pushing open position cuts) about 8% of real employees were cut.

So, when it's all said and done 35-40% of our colleagues and ourselves will be out of a job.
Click to expand...


That is SUCH an incredible lie.

Irvine is left open and it's going to effectively be specialty pharma in irvine and primary and generics business in New Jersey

This is going to be an amazing company
 




It's not a lie, it's math.

You think Brent Saunders got up in front of wall street and just pulled that 1.8B number from his arse?

How exactly do you think he plans on finding those "synergies" 450million in R&D, he already flat out said it. So the other 1.4B comes from where smart guy?

Tax rate saves a fixed amount. Everything after that = people.

Or, you explain the math.
 




Anonymous said:
It's not a lie, it's math.

You think Brent Saunders got up in front of wall street and just pulled that 1.8B number from his arse?

How exactly do you think he plans on finding those "synergies" 450million in R&D, he already flat out said it. So the other 1.4B comes from where smart guy?

Tax rate saves a fixed amount. Everything after that = people.

Or, you explain the math.
Click to expand...

I agree this will be a great company but that doesn't necessarily mean that all the reps will be brought along. The rest od the Synergies will come from corporate overlap/IT etc and sales force reductions....FROM BOTH SIDES. Actavis is still heavy sales force wise and now you add on Allergan....cuts will be coming.
 




Valeant is still a "House of Cards" from an accounting point of view. Any company is better than Valeant if you remember Enron or Tyco, who were both darlings of Wall Street until the smoke and mirrors came crashing down.

Being owned by a company like Valeant who is on borrowed-time and always just one more merger away from not being able to cover its debts, is just not a future anyone wanted. Valeant is not a company, its an accounting bubble that no one knows when it will pop!
 




Simple. The operating costs, and market cap, of this combined company is significantly greater to subtract 1.8 from than a VRX/AGN combined company - 2.7. Especially since the 2.7 would come from R&D, and Irvine versus the 1.8 coming from overlapping costs, yes some sales force redundancies

Hypothetically if the act/agn operating costs is 8 - 1.8 is pretty good with that 1.8 being equally distributed on a "best of the best" model versus a 6 - 2.7 with most of that 2.7 coming from Allergan

We know that there will be a combkned mgmt team, we know irvine will stay open, we know there is belief in R&D and there is much more of a global footprint to trim from versus the valeant "decentralized" model.

We also know that enhanced severance is built in, etc

Soooo much better on so many levels unless you are a VRX shareholder or troll
 




Anonymous said:
Valeant is still a "House of Cards" from an accounting point of view. Any company is better than Valeant if you remember Enron or Tyco, who were both darlings of Wall Street until the smoke and mirrors came crashing down.

Being owned by a company like Valeant who is on borrowed-time and always just one more merger away from not being able to cover its debts, is just not a future anyone wanted. Valeant is not a company, its an accounting bubble that no one knows when it will pop!
Click to expand...

Gee, I feel a whole lot better now.
 
















"best of the best" was language used at bausch and lomb acquisition from ista aka. Brent Saunders. They laid off the bottom 50% reps from both companies. Whichever rep in that area had the better numbers, that's who stayed.
 




I don't think VRX would have been better, but at least there was enough "history" on how they treat rep after they are bought. I am told to make clients believe "business as usual", but aesthetic doc don't know who ACT is. My integrity is on the line so I hope ACT doesn't change the way we dis business at AGN!
 












Big cuts are going to come all over. Who are we kidding- we don't have much of a pipeline (so much for the billions we spend on R&D) and they have plenty of sales representatives and management.

The writing is on the wall. Don't be blind.
 




the writing doesn't have to be "on the wall" dumbfuck - we're being acquired and it's general knowledge there will be significant cuts across the board

But thanks for leveling with everyone, you really know your stuff.
 








Top Bottom
Back
Quote